SELLAS Life Sciences Group, Inc. (SLS)

NASDAQ: SLS · IEX Real-Time Price · USD
2.19
+0.09 (4.29%)
At close: Sep 27, 2022 4:00 PM
2.25
+0.06 (2.74%)
After-hours: Sep 27, 2022 4:41 PM EDT
4.29%
Market Cap 45.01M
Revenue (ttm) 1,000,000
Net Income (ttm) -38.84M
Shares Out 20.55M
EPS (ttm) -2.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,044
Open 2.14
Previous Close 2.10
Day's Range 2.13 - 2.23
52-Week Range 2.02 - 9.92
Beta 1.76
Analysts Buy
Price Target 10.20 (+365.8%)
Earnings Date Nov 10, 2022

About SLS

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal grow... [Read more...]

Industry Biotechnology
Founded 2012
Employees 11
Stock Exchange NASDAQ
Ticker Symbol SLS
Full Company Profile

Financial Performance

In 2021, SLS's revenue was $7.60 million, an increase of 300.00% compared to the previous year's $1.90 million. Losses were -$20.70 million, 23.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for SLS stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 365.75% from the latest price.

Price Target
$10.2
(365.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of no...

5 days ago - GlobeNewsWire

SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th

NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of no...

1 week ago - GlobeNewsWire

SELLAS Life Sciences' Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclini...

- Neuroendocrine Prostate Cancer is Growing Unmet Medical Need -

1 month ago - GlobeNewsWire

SELLAS Life Sciences' Announces Election of Katherine Bach Kalin to its Board of Directors

Ms. Kalin Joins the Board with Decades of Life Sciences and Healthcare Industry Experience Ms. Kalin Joins the Board with Decades of Life Sciences and Healthcare Industry Experience

1 month ago - GlobeNewsWire

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results

– Reported Encouraging Updated Data in Q2 from Two Clinical Trials of Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors–

1 month ago - GlobeNewsWire

SELLAS Life Sciences' GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Canc...

- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines -

1 month ago - GlobeNewsWire

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 In...

The Company Continues to Evaluate Optimal Dosing for Patients with Acute Myeloid Leukemia and Lymphoma in Preparation for Phase 2 The Company Continues to Evaluate Optimal Dosing for Patients with Acute...

2 months ago - GlobeNewsWire

SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date -

3 months ago - GlobeNewsWire

SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients

SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb Co's (NYSE: BMY) nivolumab (Opdivo) in with ...

3 months ago - Benzinga

SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mes...

Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Appro...

3 months ago - GlobeNewsWire

SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th

NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of ...

3 months ago - GlobeNewsWire

Sellas' Ovarian Cancer Candidate Shows Clinical Benefit In Pretreated Patients

SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced topline data from its Phase 1/2 trial of galinpepimut-S (GPS) in WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cance...

4 months ago - Benzinga

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Com...

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone -

4 months ago - GlobeNewsWire

SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor -

4 months ago - GlobeNewsWire

SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S

Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid Leukemia (AML) Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS...

5 months ago - GlobeNewsWire

SELLAS Life Sciences' Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Pa...

- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated -

5 months ago - GlobeNewsWire

SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022 SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022

5 months ago - GlobeNewsWire

SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights

– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor –

5 months ago - GlobeNewsWire

SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor

GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc (NASDAQ: SLS) across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong Kong, ...

5 months ago - Benzinga

SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of nov...

5 months ago - GlobeNewsWire

SELLAS Life Sciences Announces Proposed Underwritten Public Offering

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of nov...

5 months ago - GlobeNewsWire

SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selecti...

- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset -

5 months ago - GlobeNewsWire

SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer

Biopharmaceutical Veteran Brings More Than 25 Years of Experience to SELLAS Biopharmaceutical Veteran Brings More Than 25 Years of Experience to SELLAS

6 months ago - GlobeNewsWire

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembro...

Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis

7 months ago - GlobeNewsWire

Sellas Life Sciences Shares Jump As China Approves Galinpepimut IND For Blood Cancer

3D189, also known as SELLAS' lead product candidate, galinpepimut-S (GPS), is an immunotherapeutic that targets the Wilms Tumor 1 (WT1) protein, which is present and over-expressed in an array of hemato...

8 months ago - Benzinga